Overcoming the hurdles to achieving glycemic control

Kenneth M Shaw1

  • 1Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital Cosham, Portsmouth, PO6 3LY, UK. ken.shaw@porthosp.nhs.uk

Insights

Optimizing glycemic control in type 2 diabetes mellitus is challenging. Once-daily gliclazide modified release improves medication adherence and HbA1c levels, with a reduced risk of hypoglycemia.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management is complex, with factors impacting glycemic control.
  • Over time, patients often experience reduced medication responsiveness and difficulty achieving target blood glucose levels.
  • Modifiable factors, including lifestyle and confounding conditions, significantly influence diabetes outcomes.

Purpose of the Study:

  • To evaluate the efficacy and adherence benefits of gliclazide modified release in T2DM patients.
  • To compare glycemic control and hypoglycemia risk with gliclazide modified release versus glimepiride.

Main Methods:

  • A study comparing gliclazide modified release with glimepiride in T2DM patients.
  • Assessment of medication adherence and glycemic control (HbA1c levels).
  • Evaluation of hypoglycemia incidence as a key safety outcome.

Main Results:

  • Gliclazide modified release demonstrated improved medication adherence compared to standard regimens.
  • Patients on gliclazide modified release achieved better glycemic control, indicated by lower HbA1c levels.
  • The study showed a reduced risk of hypoglycemia with gliclazide modified release.

Conclusions:

  • Once-daily gliclazide modified release enhances patient adherence and improves glycemic outcomes in T2DM.
  • Gliclazide modified release offers a safer alternative with a lower risk of hypoglycemia.
  • Simplifying treatment regimens, like with once-daily formulations, is crucial for effective T2DM management.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...